Evaluation of vilazodone for the treatment of depressive and anxiety disorders

Volume: 20, Issue: 3, Pages: 251 - 260
Published: Nov 26, 2018
Abstract
Major Depressive Disorder (MDD) and General Anxiety Disorder (GAD) significantly contribute to the global burden of disease. Vilazodone, a combined serotonin reuptake inhibitor and 5-HT1A partial agonist, is an approved therapy for the treatment of MDD and which has been further investigated for GAD. Areas covered: This article covers the pharmacokinetics and pharmacodynamics of vilazodone and provides an evaluation of the clinical usefulness of...
Paper Details
Title
Evaluation of vilazodone for the treatment of depressive and anxiety disorders
Published Date
Nov 26, 2018
Volume
20
Issue
3
Pages
251 - 260
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.